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Abstract
There is an increasing body of evidence that synovitis plays a
role in the progression of osteoarthritis and that overproduction
of cytokines and growth factors from the inflamed synovium can
influence the production of degradative enzymes and the
destruction of cartilage. In this study, we investigate the role of
synovial macrophages and their main proinflammatory cytokines,
interleukin (IL)-1 and tumour necrosis factor-alpha (TNF-α), in
driving osteoarthritis synovitis and influencing the production of
other pro- and anti-inflammatory cytokines, production of matrix
metalloproteinases, and expression of aggrecanases in the
osteoarthritis synovium. We established a model of cultures of
synovial cells from digested osteoarthritis synovium derived from
patients undergoing knee or hip arthroplasties. By means of anti-
CD14-conjugated magnetic beads, specific depletion of
osteoarthritis synovial macrophages from these cultures could
be achieved. The CD14+-depleted cultures no longer produced
significant amounts of macrophage-derived cytokines like IL-1
and TNF-α. Interestingly, there was also significant
downregulation of several cytokines, such as IL-6 and IL-8 (p <
0.001) and matrix metalloproteinases 1 and 3 (p  < 0.01),
produced chiefly by synovial fibroblasts. To investigate the
mechanisms involved, we went on to use specific
downregulation of IL-1 and/or TNF-α in these osteoarthritis
cultures of synovial cells. The results indicated that
neutralisation of both IL-1 and TNF-α was needed to achieve a
degree of cytokine (IL-6, IL-8, and monocyte chemoattractant
protein-1) and matrix metalloproteinase (1, 3, 9, and 13)
inhibition, as assessed by enzyme-linked immunosorbent assay
and by reverse transcription-polymerase chain reaction (RT-
PCR), similar to that observed in CD14+-depleted cultures.
Another interesting observation was that in these osteoarthritis
cultures of synovial cells, IL-1β production was independent of
TNF-α, in contrast to the situation in rheumatoid arthritis. Using
RT-PCR, we also demonstrated that whereas the ADAMTS4 (a
disintegrin and metalloprotease with thrombospondin motifs 4)
aggrecanase was driven mainly by TNF-α, ADAMTS5 was not
affected by neutralisation of IL-1 and/or TNF-α. These results
suggest that, in the osteoarthritis synovium, both inflammatory
and destructive responses are dependent largely on
macrophages and that these effects are cytokine-driven through
a combination of IL-1 and TNF-α.
Introduction
Osteoarthritis (OA), one of the most common diseases among
mammals, can be considered as part of the ageing process.
Mechanical factors such as a history of joint trauma or a high
body mass index are recognised risk factors for OA, as are
certain endogenous factors like type II collagen mutations and
acetabular dysplasia. There is also a growing body of evidence
that synovial inflammation is implicated in many of the signs
and symptoms of OA, including joint swelling and effusion
[1,2]. Histologically, the OA synovium shows hyperplasia with
an increased number of lining cells and a mixed inflammatory
ADAMTS = a disintegrin and metalloprotease with thrombospondin motifs; ELISA = enzyme-linked immunosorbent assay; FACS = fluorescence-
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infiltrate consisting mainly of macrophages [3]. Some degree
of synovitis has been reported even in early OA [2].
Synovitis in OA is likely to contribute to disease progression,
as judged by the correlation between biological markers of
inflammation, like C-reactive protein and cartilage oligomeric
matrix protein, with the progression of structural changes in
OA [4-6]. The overproduction of cytokines and growth factors
from the inflamed synovium may play a role in the pathophysi-
ology of OA. The low-grade OA synovitis is itself cytokine-
driven, although the levels of proinflammatory cytokines are
lower than in rheumatoid arthritis (RA). In particular, tumour
necrosis factor-alpha (TNF-α) and interleukin (IL)-1 have been
suggested as key players in OA pathogenesis [7-9], both in
synovial inflammation and in activation of chondrocytes. These
cytokines can stimulate their own production and induce syn-
ovial cells and chondrocytes to produce IL-6, IL-8, and leuko-
cyte inhibitory factor as well as stimulate protease and
prostaglandin production [1,10]. The hypothesis that TNF-α
and IL-1 are key mediators of articular cartilage destruction
has raised the possibility of anti-cytokine therapy in OA or the
design of disease-modifying osteoarthritic drugs [1,11,12].
If it is accepted that synovial inflammation and the production
of proinflammatory and destructive mediators from the OA
synovium are of importance for the symptoms and progression
of OA, it is an important question which cell type in the OA
synovium is responsible for maintaining synovial inflammation.
In RA, in which the macrophage is the main promoter of dis-
ease activity, macrophage-produced TNF-α is a major thera-
peutic target. Unfortunately, much less is known about the role
of macrophages in OA. Histological studies have demon-
strated that OA synovial macrophages exhibit an activated
phenotype and that they produce both proinflammatory
cytokines and vascular endothelial growth factor [13]. Syno-
vial macrophage differentiation differs between inflammatory
and non-inflammatory OA [14]. In mouse models of osteo-
phyte formation induced by injections of transforming growth
factor-beta or of collagenase, depletion of macrophages by
injection of clodronate-laden liposomes led to marked inhibi-
tion of osteophytes, suggesting that these cells are important
for this form of structural damage [15,16].
Some of the matrix metalloproteinases (MMPs) have degrada-
tive effects on the extracellular matrix and have been sug-
gested [17,18] as important cofactors or disease mediators in
OA. MMP-1 and MMP-13 are capable of cleaving collagen
type II, whereas MMP-3 is active against other components of
the extracellular matrix, such as fibronectin and laminin.
Although there has been some interest in MMP inhibitors as
therapeutic agents in OA [19-21], the importance of these
molecular pathways is not entirely clear, nor are there conclu-
sive data on whether macrophages and macrophage-pro-
duced cytokines stimulate MMP production in the OA
synovium.
Articular cartilage contains high concentrations of the large
aggregating proteoglycan aggrecan. The high negative charge
density of the glycosaminoglycan chains on aggrecan mono-
mers in cartilage proteoglycan is essential for the ability of
articular cartilage to withstand compressive deformation. The
depletion of aggrecan from articular cartilage, as evidenced by
the release of aggrecan fragments into the synovial fluid, is a
central pathophysiological event in OA. It has been demon-
strated that the release of aggrecan from both normal and OA
cartilage involves a specific cleavage by a group of enzymes
known as the aggrecanases and that it does not involve the
MMPs [22,23]. The aggrecanases are members of the family
of the ADAMTS (a disintegrin and metalloprotease with throm-
bospondin motifs). To date, several such enzymes have been
identified, among them aggrecanase-1 (ADAMTS4) [24] and
aggrecanase-2 (ADAMTS5) [25]. IL-1 and TNF-α can mediate
the catabolism of aggrecan, but whereas ADAMTS5 is consti-
tutively expressed, ADAMTS4 is induced after IL-1 or TNF
treatment of cartilage explants [26]. It has not been ascer-
tained whether these cytokines act directly on the aggreca-
nase enzyme; however, in OA cartilage, aggrecanase is
upregulated in the absence of catabolic stimulation [27]. More
information is needed about the regulation of the aggreca-
nases, in particular whether they are driven by proinflammatory
cytokines produced by macrophages or other cells.
We set up a model of cultures of synovial cells from digested
OA synovium. These cells have the advantage of spontane-
ously producing a variety of both pro- and anti-inflammatory
cytokines, including TNF-α, IL-1, and IL-10, as well as the
major MMPs and tissue inhibitors of MMPs (TIMPs) [28]. In
this study, we used anti-CD14-conjugated magnetic beads to
achieve specific depletion of OA synovial macrophages in
order to investigate the importance of these macrophages for
the spontaneous production of proinflammatory cytokines and
destructive MMPs in the OA synovium. We also assessed, by
means of specific neutralisation of macrophage-produced
TNF-α and IL-1, the contribution of these two proinflammatory
cytokines on the production of each other, on other proinflam-
matory mediators, on the expression and production of various
MMPs and TIMPs, and on ADAMTS4 and ADAMTS5 gene
expression.
Materials and methods
Preparation of synovial specimens
OA synovial specimens were obtained from 19 patients under-
going knee or hip replacement surgery (14 females, 5 males;
ages 55 to 84 years) after ethical permission had been given
by the Gwent and Bro Taf National Health Service Trusts eth-
ical committees. None of these patients was taking corticos-
teroids or any kind of disease-modifying antirheumatic drug.
The synovium was dissociated by cutting it into small pieces
and digesting it with collagenase and DNAse as described
[28]. After the 2-hour digestion, the cell suspension was fil-
tered through a 100-μm filter (BD Biosciences, San Jose, CA)Available online http://arthritis-research.com/content/8/6/R187
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to remove any undigested tissue. The filtered cell suspension
was centrifuged at 300 g for 10 minutes. The supernatant was
collected and centrifuged again for 10 minutes at 300 g. After
the second spin, the two pellets were combined and resus-
pended into 10 ml of RPMI medium 1640 (with 2 mM l-
glutamine and 10 μg/ml penicillin-streptomycin) supple-
mented with 10% heat-inactivated foetal calf serum (FCS).
Flow cytometry analysis of the OA synovial cells showed that
the synovium was comprised mainly of fibroblast-like synovio-
cytes with 2% to 7% macrophages, less than 0.5% neu-
trophils, and less than 0.1% T cells.
Peripheral blood mononuclear cell preparation
The macrophage depletion system was tested using periph-
eral blood mononuclear cells (PBMCs) to ensure that the
depletion would be effective. Whole blood was extracted from
healthy human volunteers and separated out using Ficoll-
Hypaque (Sigma-Aldrich, St. Louis, MO, USA) density gradi-
ent centrifugation. The PBMCs were taken off, washed,
counted, and resuspended in 10 ml of RPMI 1640 medium
(supplemented as above).
Macrophage depletion
A magnetic-activated cell sorting (MACS) separation column
system (Miltenyi Biotec, Bergisch Gladbach, Germany) was
assembled by placing a MiniMacs separation column into the
magnetic component and was washed with 500 μl of deple-
tion buffer. To prepare a population of cells depleted of
CD14+ cells, either PBMCs or synovial cells were first passed
through a 30-μm MiniMacs filter to remove cell aggregates.
The resulting cell suspension was centrifuged at 300 g for 10
minutes. The pellet was resuspended into 80 μl of depletion
buffer (comprising phosphate-buffered saline [pH 7.2] supple-
mented with 0.5% bovine serum albumin and 2 mM EDTA) per
107 cells. Half the cells were removed to act as the total (unde-
pleted) cell population. Twenty microlitres of MACS CD14
microbeads was added per 107 cells to the other half, which
was then mixed thoroughly and incubated on ice for 15 min-
utes before being washed and resuspended in 500 μl of
depletion buffer.
The CD14 magnetically labelled cells were applied to the col-
umn and the effluent was collected. Then, 3 × 500 μl of deple-
tion buffer was applied to the column and the effluent was
collected. The effluent (2 ml) contained the cells depleted of
CD14+ cells, as the magnetically labelled CD14-labelled cells
were retained within the separation column.
To deplete T cells from the synovial cell culture, 20 μl of CD3
microbeads was added per 107 cells. The cells were incu-
bated again on ice for 15 minutes, 10 times the labelling vol-
ume of depletion buffer was added, and the cells were
pelleted by centrifugation at 300 g for 10 minutes. Then, the
cell pellet was resuspended into 500 μl of depletion buffer,
and the cells were separated using the same protocol as for
CD14-labelled cells. The CD3-depleted population of PBMCs
was shown by flow cytometry to be less than 0.1% CD3+
when stained with anti-CD3 human fluorescein isothiocyanate
(BD Biosciences, San Jose, CA, USA).
After macrophage or T-cell depletion in OA synovial cells, a
cell count was performed on the retained total population and
the depleted population. After the cell count, the two popula-
tions were resuspended in RPMI 1640 (with 2 mM l-glutamine
and 10 μg/ml penicillin-streptomycin and supplemented with
10% heat-inactivated FCS) at equal cell concentrations and
plated at 1 ml/well into a 12-well plate. Due to individual varia-
tions between patients, the densities at which cells could be
plated varied between 1 × 105 and 1 × 106 cells per well,
although the total cell population and the depleted cell popu-
lation were always plated at the same density for each patient.
Cells were left to adhere for 24 hours before the supernatants
were removed and the cells collected by trypsination and pel-
leted by centrifugation at 3,000 rpm for 5 minutes.
Anti-cytokine experiments
In these experiments, OA cultures of synovial cells were pre-
pared using the protocol above. Two million cells were plated
into 4 wells on a 24-well plate in 1 ml of RPMI 1640 supple-
mented with 10% FCS (as above). The cells were left
untreated, incubated with the p75 TNF-soluble receptor-
immunoglobulin (Ig) fusion protein etanercept (Enbrel; 100
μg/ml), incubated with a neutralising anti-IL-1β antibody pur-
chased from R&D Systems, Inc. (Minneapolis, MN, USA) (10
μg/ml), or incubated with a combination of Enbrel and anti-IL-
1β. Although Enbrel binds both TNF-α and lymphotoxin, it
would have a selective effect on TNF-α in this system because
neither OA nor RA cultures of synovial cells produce detecta-
ble amounts of lymphotoxin [28,29]. After incubation for 48
hours at 37°C and 5% CO2, the supernatants were removed
and the cells collected by trypsination and pelleted by centrif-
ugation at 3,000 rpm for 5 minutes. Higher doses (up to 2 mg/
ml Enbrel and up to 200 μg/ml anti-IL-1β) and longer times of
exposure (up to 96 hours) of these cytokine inhibitors did not
increase the inhibitory effects observed (data not shown). As
judged by microscopy, the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide assay, the mRNA levels of the
housekeeping gene GAPDH  (glyceraldehyde-3-phosphate
dehydrogenase) (see Figure 5 later in text), and the caspase-
3 assay (data not shown), neither of these two cytokine inhib-
itors caused significant apoptosis or cell death.
Analysis of cytokines and matrix MMPs
To examine the differences in cytokine production between
the primary OA synovial cell cultures and those depleted of
macrophages, as well as the synovial cell cultures incubated
with anti-cytokine antibodies, the supernatants were examined
by enzyme-linked immunosorbent assay (ELISA). Superna-
tants were analysed for TNF-α, IL-1β, IL-6, IL-8, and monocyte
chemoattractant protein-1 (MCP-1) by ELISA kits purchasedArthritis Research & Therapy    Vol 8 No 6    Bondeson et al.
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from Biosource International (Camarillo, CA, USA) and R&D
Systems, Inc. The production of MMP-1, MMP-3, MMP-9,
MMP-13, and their inhibitor TIMP-1 was also examined by
ELISA as described [28].
RNA extraction and reverse transcription-polymerase 
chain reaction analysis
Total RNA was isolated from cell pellets as previously
described [30] and isolated using TRIreagent (Sigma-Aldrich)
and RNeasy (Qiagen Ltd., Crawley, UK) according to the man-
ufacturers' protocols. Reverse transcription-polymerase chain
reaction (RT-PCR) analysis was performed using an RNA
PCR kit (PerkinElmer LAS (UK) Ltd, Beaconsfield, Bucks, UK)
as described [31] using oligonucleotide primers correspond-
ing to cDNA sequences for the ADAMTS4 and ADAMTS5
aggrecanases, MMPs, TIMPs, and link protein (Table 1). After
an initial denaturation step of 1 minute at 95°C, amplification
consisted of between 30 and 60 cycles of 1 minute at 95°C,
45 seconds at the primer annealing temperature, 30 seconds
at 72°C followed by a final extension step of 5 minutes at
72°C. The PCR products were visualised on a 2% agarose gel
(containing 0.5 μg/ml ethidium bromide), and their nucleotide
sequences were verified using an ABI 310 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). The NIH Imaging
system (National Institutes of Health, Bethesda, MD, USA)
was used to quantify the bands on the gels and to standardise
them against the GAPDH control.
Results
OA synovial cell cultures spontaneously secrete a variety of
pro- and anti-inflammatory cytokines in quantities readily
detectable by ELISA [28]. These mediators include the mac-
rophage-produced TNF-α, IL-1β, and large amounts of IL-6, IL-
8, and MCP-1. They also produce large amounts of the major
MMPs (1, 3, 9, and 13) and their main endogenous inhibitor,
TIMP-1 (Table 2). Importantly, it is also possible to study the
expression of various degradative enzymes by RT-PCR.
Macrophage and T-cell depletion studies
A method of isolating monocytes/macrophages or T cells by
using separator columns and anti-CD14 or anti-CD3 antibod-
ies coupled with magnetic beads was first set up in peripheral
blood by using antibodies purchased from Miltenyi Biotec. As
judged by fluorescence-activated cell sorting (FACS) analysis
using fluorescent antibodies to detect the monocyte and lym-
phocyte populations and by functional studies (lipopolysac-
charide-induced TNF-α production), this method of monocyte
depletion worked well in the PBMC model (Figure 1).
Table 1
Oligonucleotide primers used for reverse transcription-polymerase chain reaction
Target template Polymerase chain reaction primers Product size (bp) Annealing temperature (°C)
GAPDH 5'-TGGTATCGTGGAAGGACTCAT
5'-GTGGGTGTCGCTGTTGAAGTC
370 53
ADAMTS4 5'-GTCTGTGTCCAGGGCCGATGC
5'-GCCGCCGAAGGATCTCCAGAA
541 61.8
ADAMTS5 5'-GCGGATGTGTGCAAGCTGACC
5'-AGTAGCCCATGCCATGCAGGA
487 57.4
MMP-1 5'-ACAAATCCCTTCTACCCGGAA
5'-GGATCCATAGATCGTTTATAT
314 50.8
MMP-3 5'-CTTTTGGCGAAAATCTCTCAG
5'-AAAGAAACCCAAATGCTTCAA
404 50
MMP-9 5'-GGCCTCCAACCACCACCACA
5'-CGCCCAGAGAAGAAGAAAAGC
400 61
MMP-13 5'-TTCTGGCACACGCTTTTCCTC
5'-GGTTGGGGTCTTCATCTCCTG
273 53
TIMP-1 5'-CCACCTTATACCAGCGTTAT
5'-CCTCACAGCCAACAGTGTAGG
282 54
TIMP-2 5'-GTGGACTCTGGAAACGACAT
5'-TCTTCTTCTGGGTGGTGCTCA
265 54
TIMP-3 5'-GGGAAGAAGCTGGTAAAGGAG
5'-GCCGGATGCAGGCGTAGTGTT
418 54
Link protein 5'-GGAAGCAGAGCAAGCCAAGGT
5'-GAAGGAGGCGATCACAGCATC
448 56.1
Primer sequences correspond to sequences for human cDNAs deposited to GenBank. Where a mixed base is indicated (that is, for GAPDH), the 
sequence also corresponds to the analogous rat cDNA. ADAMTS, a disintegrin and metalloprotease with thrombospondin motifs; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of matrix metalloproteinase.Available online http://arthritis-research.com/content/8/6/R187
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The same method was then used in OA cultures of synovial
cells. FACS analysis again demonstrated effective depletion
of macrophages from the synovial cell cultures and recovery of
a relatively pure macrophage population from the column (Fig-
ure 2a). There was a marked reduction in secreted TNF-α from
macrophage-depleted cultures (CD14), indicating effective
depletion, whereas T-cell depletion (CD3) had no effect (Fig-
ure 2b), thus ruling out significant non-specific binding to the
column. Due to the extremely low number of T cells in the OA
synovium (<0.1%), it was not possible to detect the OA syno-
vial T-cell population by FACS analysis.
In a series of 10 experiments using samples from different
patients, OA synovium was digested as specified above. Half
of the sample was put into culture directly and the other half
was macrophage-depleted before being put to culture. The
spontaneous production of TNF-α and IL-1 was almost totally
inhibited in the CD14+-depleted cultures (Figure 3), which is
as it should be because these two cytokines are macrophage-
produced. Interestingly, there was also potent (70% to 80%)
inhibition of several proinflammatory cytokines (namely IL-6, IL-
8, and MCP-1) produced mainly by synovial fibroblasts. Both
MMP-1 and MMP-3 were also decreased by 60%, suggesting
that the macrophage is a major regulator of the production of
both MMPs and proinflammatory cytokines (Figure 3).
Inhibition of macrophage-produced cytokines
A series of nine experiments were performed using OA syn-
ovium from different donors, digested and cultured as speci-
fied above, to investigate the effect of selective inhibition of
TNF-α (via excess of the soluble TNF receptor-Ig fusion pro-
tein Enbrel) and/or IL-1 (via excess of a neutralising anti-IL-1β
antibody) on various cytokines and MMPs. These OA cultures
of synovial cells were left untreated or were treated with
excess neutralising anti-IL-1β antibody, excess Enbrel, or both
of these anti-cytokine strategies. There was effective neutrali-
sation of TNF-α and IL-1β in cultures treated with Enbrel and
the neutralising anti-IL-1β antibody, respectively (Figure 4a).
Importantly, we could observe no significant inhibitory effect of
Enbrel on IL-1β production or of the neutralising anti-IL-1β
antibody on TNF-α production (Figure 4a), irrespective of
dose of the cytokine inhibitor in question and of time of expo-
sure. This is in contrast to the situation in RA, in which IL-1 is
strongly TNF-dependent in cultures of synovial cells [32];
these results would indicate that in OA, there is a redundancy
between IL-1 and TNF, rather than a 'cytokine cascade' with
either of these cytokines controlling the production of the
other (Figure 4a). Both Enbrel and the neutralising anti-IL-1β
antibody decreased the spontaneous production of IL-6 by
40% (p < 0.01); there was an additive effect, and 60% inhibi-
tion (p < 0.001) was achieved when both IL-1 and TNF were
neutralised. The production of IL-8 was decreased by either
Enbrel (p < 0.05) or the neutralising anti-IL-1β antibody (p <
0.01); again there was an additive effect, and 60% inhibition
(p < 0.001) was achieved when both IL-1 and TNF were neu-
tralised. The production of MCP-1 was not significantly
affected by the neutralising anti-IL-1β antibody, although it was
decreased (p < 0.05) by Enbrel or the combination of the two
(p < 0.01) (Figure 4a).
We also studied the effect of Enbrel and/or the neutralising
anti-IL-1β antibody on the spontaneous production of the
major MMPs (1, 3, 9, and 13). The neutralising anti-IL-1β anti-
body alone had no significant effect on any of these MMPs
(Figure 4b). Enbrel induced a significant (p < 0.05) reduction
of MMP-1 and MMP-3 production. In contrast, all of these
MMPs were significantly inhibited by the combination of
Enbrel and the neutralising anti-IL-1β antibody. The production
of the important collagenases MMP-1 and MMP-13 was
potently decreased (50% to 60%; p < 0.001), and the pro-
Table 2
Production of cytokines and matrix metalloproteinases
Untreated Anti-IL-1 Enbrel Anti-IL-1 and Enbrel
Mean SEM Mean SEM Mean SEM Mean SEM
TNF (n = 7) 14.035 5.208 10.863 3.524 1.262 0.4787 1.291 0.5701
IL-1 (n = 7) 2.0587 1.216 0.00357 0.003858 0.767 0.310 0.002857 0.00291
IL-6 (n = 7) 1,218,830 374,998 735,202.7 180398.9 725,517 187,147.4 378,930.3 103,236.2
IL-8 (n = 7) 325.62 108.67 211.81 64.35 245.04 75.69 134.75 37.48
MCP-1 (n = 7) 62.29 15.43 60.29 16.17 51.58 13.95 41.56 11.65
MMP-1 (n = 7) 1,398.1 513.0 1,431.9 617.6 1,083.4 448.9 644.9 242.7
MMP-3 (n = 7) 4,508.7 1,840.7 4,920.8 2,197.1 3,953.4 1,789.2 3,169.7 1,543.6
MMP-9 (n = 6) 23.5 7.2 23.67 6.589 20.83 6.37 19.83 6.427
MMP-13 (n = 7) 3,772.3 1,428.5 4,262.7 1,312.1 2,730.5 715.4 1,644 538.2
IL, interleukin; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinase; SEM, standard error of the mean; TNF, tumour necrosis 
factor.Arthritis Research & Therapy    Vol 8 No 6    Bondeson et al.
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duction of MMP-3 (p < 0.01) and MMP-9 (p < 0.05) was also
downregulated. There was no effect of either anti-cytokine
strategy on the spontaneous production of TIMP-1 (data not
shown).
Analysis of RNA expression for MMPs, TIMPs, and 
aggrecanases using RT-PCR
Using RT-PCR technology, we investigated the effect of selec-
tive inhibition of TNF-α and/or IL-1 on MMPs, TIMPs, and
ADAMTS metalloproteinases in the OA synovial cell cultures.
These experiments used the cell pellets from the experiments
described earlier (eight patients in all), which were freezer-
stored before RNA was extracted and analysed using RT-
PCR. MMP-1 was significantly (p < 0.05) inhibited by neutral-
ising IL-1 but only marginally affected by Enbrel. Neutralising
both cytokines led to significant (p < 0.01) inhibition of MMP-
1 (Figures 5 and 6). With regard to MMP-13, the effect of neu-
tralising each cytokine on its own was again less potent,
although a combination of Enbrel and the neutralising anti-IL-
1β antibody led to significant (p < 0.01) downregulation of this
enzyme via a synergistic effect (Figures 5 and 6). The effect on
MMP-3 was similar (data not shown). With regard to the
expression of various TIMPs, we observed that although TIMP-
1 and TIMP-2 were unaffected, TIMP-3 was inhibited by a
combination of Enbrel and the neutralising anti-IL-1β antibody
(Figure 5). These PCR results agree well with the ELISA
results described earlier (Figure 4b). The reason the effects
observed are more marked in the PCR system is probably that
when the OA synovial cells are put into culture, they are highly
active and produce large amounts of MMPs. With time, this is
inhibited by neutralisation of the macrophage-produced, proin-
flammatory cytokines driving MMP production, but by then,
large quantities of these MMPs have already been produced,
thus blurring the results. In contrast, the PCR findings reflect
the state of the cells 2 days after addition of the Enbrel and/or
the neutralising anti-IL-1β antibody. There appears to be a dis-
crepancy with regard to MMP-1: whereas the neutralising anti-
IL-1β antibody decreases its expression at the RNA level (Fig-
ure 5), there is no significant effect on its production (Figure
4b). This might be explained by the activation of latent MMP
activity but no further production of 'new' enzyme.
Surprisingly, we also found that link protein is significantly (p <
0.01) inhibited by Enbrel or by a combination of Enbrel and the
neutralising anti-IL-1β antibody (Figures 5 and 6). These
results suggest that anabolic synthesis of aggrecan aggregate
components may be affected by neutralisation of these
cytokines.
We also studied the expression of the aggrecanases
ADAMTS4 and ADAMTS5 in five patients. There was no effect
of either Enbrel or the neutralising anti-IL-1β antibody on
ADAMTS5 expression, nor was it at all affected by a
combination of these treatments (Figure 7). Thus, this aggre-
canase appears to be constitutive in OA cultures of synovial
Figure 1
Fluorescence-activated cell sorting (FACS) analysis of monocyte/mac- rophage depletion in peripheral blood mononuclear cells (PBMC) Fluorescence-activated cell sorting (FACS) analysis of monocyte/mac-
rophage depletion in peripheral blood mononuclear cells (PBMC). (a) 
The left panel shows FACS analysis of forward scatter (FSC) and side 
scatter (SSC) of unlabeled PBMC, with the approximate monocyte 
population indicated with a circle. In the right panels, cells have been 
incubated with an anti-CD14 phycoerythrin antibody, clearly showing 
the distinct population of CD14+ cells on FACS (upper panel) and in a 
histogram (lower panel). (b) The corresponding panels show mono-
cyte-depleted PBMC. In the left panel, the monocyte population is 
reduced, although the debris and cell clusters blur this effect. In the 
right upper panel, the CD14+ population virtually disappears, as con-
firmed by the histogram in the right lower panel. (c) The corresponding 
panels show the enriched monocytes/macrophages. In the left panel, 
although there is still a fair amount of debris and cell clusters, the 
monocyte population is considerably enriched. In the right upper panel, 
the CD14+ population is also very much enriched, as confirmed by the 
histogram in the panel below. (d) A functional assay using enzyme-
linked immunosorbent assay analysis of spontaneous and lipopolysac-
charide-stimulated (open bars) tumour necrosis factor-alpha (TNF-α) 
production in monocyte/macrophage-depleted and -undepleted 
PBMCs verifies that the monocyte/macrophage depletion is effective.Available online http://arthritis-research.com/content/8/6/R187
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cells. In contrast, ADAMTS4 was significantly (p < 0.05) inhib-
ited by Enbrel and more potently (p < 0.01) inhibited by a com-
bination of Enbrel and the neutralising anti-IL-1β antibody
(Figures 6 and 7). The lower band in the ADAMTS4 panel in
Figure 7 represents a newly discovered splice variant of
ADAMTS4 [33].
Discussion
In recent years, its pivotal importance in RA having been
clearly established, the synovial macrophage has begun to
attract interest in OA also. Imaging studies have demonstrated
synovitis in both early and late OA [34-36], even in joints in
which it could not be detected clinically. Immunohistochemical
studies have found that, particularly in early OA, this synovitis
has a mononuclear cell infiltrate, with considerable production
of proinflammatory cytokines like TNF-α and IL-1β and
destructive enzymes like MMP-1 and MMP-3 [2,37]. This
agrees well with our data from the OA synovial cell culture
model, which exhibits spontaneous production of TNF-α and
IL-1β and many other cytokines and MMPs.
The first major finding from this study is that OA cultures of
synovial cells can be selectively depleted of macrophages and
that macrophage depletion results in downregulation of
Figure 2
FACS analysis of OA synovial cells FACS analysis of OA synovial cells. (a) Fluorescence-activated cell sorting (FACS) analysis of total (upper three panels) and CD14+-depleted 
(lower three panels) osteoarthritis (OA) cultures of synovial cells. The upper three panels show FACS analysis of forward scatter/side scatter (FSC/
SSC) (left panel), analysis of FL2+ cells after incubation with the anti-CD14 phycoerythrin antibody with the CD14+ population indicated in region R2 
(middle panel), and the CD14+ cells in this region showing as FL2+ in a histogram (right panel). The corresponding lower three panels show diminu-
tion of the macrophage population on FSC/SSC (left panel), disappearance of CD14+ cells (middle panel), and a histogram (right panel) after deple-
tion of CD14+ cells. (b) A functional assay using the spontaneous tumour necrosis factor-alpha (TNF-α) production from the OA synovial cells 
shows effective inhibition of TNF-α production in CD14+-depleted cells from two patients (left panel), whereas CD3+ cell depletion has no effect.Arthritis Research & Therapy    Vol 8 No 6    Bondeson et al.
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several fibroblast-produced cytokines and MMPs (Figures 2
and 3). This would indicate that in these densely plated cul-
tures, the macrophages play a role in perpetuating inflamma-
tory and destructive responses from the synovial fibroblasts.
The cultures enriched for OA macrophages produce only very
limited amounts of these MMPs (data not shown), and thus the
macrophage depletion per se cannot be held responsible for
this effect. That the regulation is not tighter than observed is
probably due to the fibroblasts having quite an active pheno-
type already when taken into culture, with considerable spon-
taneous production of various mediators. But once the
macrophages are removed, the synovial fibroblasts downreg-
ulate their production of both proinflammatory cytokines and
destructive MMPs.
In a mouse model of experimental OA, synovial lining macro-
phages are pivotal cells, mediating osteophyte formation and
other OA-related pathology [15]. The effects of macrophage
depletion observed in the present study may well provide an
explanation of these effects, either directly due to the inhibition
of fibroblast-produced cytokines and/or MMPs or indirectly
due to cytokine-mediated inhibition of the production of
growth factors [16].
The majority of studies of the regulation of cytokines and
destructive enzymes in arthritis have relied on the stimulation
of outgrown synovial fibroblasts with various catalytic mole-
cules, among them TNF-α and IL-1β. To investigate the mech-
anisms behind the macrophage stimulation of other cells in OA
cultures of synovial cells, we instead used specific neutralisa-
tion of TNF-α and/or IL-1β, as previously described in RA
[32,38]. The second major finding from this study is that
although the effects of inhibiting each cytokine on its own are
less impressive, neutralisation of both TNF-α and IL-1β results
in significant inhibition of fibroblast-produced cytokines and
MMPs to a degree roughly comparable to that induced by
macrophage depletion. This would suggest that in these OA
cultures of synovial cells, the macrophage perpetuates
inflammatory and destructive responses from the synovial
fibroblasts through a combination of TNF-α and IL-1β (Figures
Figure 3
Effect of macrophage depletion on cytokine and matrix metalloprotein- ase (MMP) production in osteoarthritis (OA) synovial cells Effect of macrophage depletion on cytokine and matrix metalloprotein-
ase (MMP) production in osteoarthritis (OA) synovial cells. OA cultures 
of synovial cells were either left intact or macrophage-depleted, as 
described in Materials and methods. Cells were left to adhere for 24 
hours before the supernatants were removed for enzyme-linked immu-
nosorbent assay analysis of cytokines and MMPs. Data are expressed 
as the percentage of cytokine/MMP production in the depleted culture 
as compared with the undepleted one. The standard error of the mean 
is given (n = 7–9). IL, interleukin; MCP, monocyte chemoattractant pro-
tein; TNF, tumour necrosis factor.
Figure 4
Effect of neutralisation of tumour necrosis factor (TNF)-α and/or inter- leukin (IL)-1 on cytokine and matrix metalloproteinase (MMP) produc- tion in osteoarthritis synovial cells Effect of neutralisation of tumour necrosis factor (TNF)-α and/or inter-
leukin (IL)-1 on cytokine and matrix metalloproteinase (MMP) produc-
tion in osteoarthritis synovial cells. In these experiments, 2 × 106 cells 
per well were plated into 4 wells on a 24-well plate in 1 ml of RPMI 
1640 supplemented with 10% foetal calf serum. The cells in these 4 
wells were left untreated, incubated with the p75 TNF-soluble receptor-
immunoglobulin fusion protein etanercept (Enbrel), incubated with a 
neutralising anti-IL-1β antibody, or incubated with a combination of 
etanercept and anti-IL-1β, as described in Materials and methods. After 
incubation for 48 hours, the supernatants were removed for enzyme-
linked immunosorbent assay analysis of various cytokines (a) and 
MMPs (b). The data are expressed as percentage of the production of 
untreated cells, and the standard error of the mean is given (n = 6–7).Available online http://arthritis-research.com/content/8/6/R187
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4 and 5). There appears to be a redundancy in the system, and
the neutralisation of just one of these cytokines is not suffi-
cient. The reason the effect of macrophage depletion, or com-
bined inhibition of TNF-α and IL-1β, does not inhibit IL-6 and
IL-8 by more than 60% is probably due to the fact that the OA
synovial fibroblasts express an activated phenotype when put
into culture and are thus able to produce both cytokines and
MMPs for some time before being gradually downregulated
when the stimulus is removed.
In RA, it is well established that there is a 'cytokine cascade'
with TNF-α at the top. The production of IL-1, IL-6, IL-8, and
granulocyte macrophage colony-stimulating factor is inhibited
when TNF-α is neutralised [32], a discovery that has led to the
emergence of anti-TNF-α therapy in RA [39]. It is known that
the macrophage signal transduction leading to TNF-α and IL-
1β induction is stimulus-specific with regard to nuclear factor-
kappa B (NF-κB) dependence [40-42], and some data sup-
port differences in the regulation of TNF-α and IL-1β in RA and
in OA, with stronger NF-κB dependence observed in RA
[[38,43,44] versus [28]]. The third major finding in this study
points out another difference between the RA and the OA syn-
ovium: IL-1β is not TNF-α-dependent. Nor is there any effect
on TNF-α production when IL-1β is neutralised, again sug-
gesting a redundancy between these two cytokines in the OA
synovium (Figure 4a). The possibility of using anti-IL-1 or anti-
TNF-α strategies in OA has been discussed for some time,
with some early reports on record [45,46]. Due to the absence
of a 'cytokine cascade' in OA with regard to the regulation of
TNF-α and IL-1β in the OA synovium (as demonstrated here),
it appears unlikely that the neutralisation of either of these
cytokines would affect the production of the other. It is still
quite possible that either TNF-α or IL-1β has other significant
downstream effects to render such therapy worthwhile, partic-
ularly with regard to synovial inflammation.
The fourth major finding from this study is that, whereas
ADAMTS5 is not driven by TNF-α or IL-1β in the OA synovium,
ADAMTS4 expression is reduced by TNF-α blockade and is
significantly downregulated when both TNF-α and IL-1β are
neutralised (Figures 6 and 7). This finding will have
significance for further research concerning the regulation of
these enzymes. There is evidence that ADAMTS4 is upregu-
lated by IL-1 in various cartilage systems [27,47,48], but this
is the first study to demonstrate that in the OA synovium, this
aggrecanase is driven by TNF-α and IL-1β. In another study,
using human OA fibroblasts, we found that ADAMTS4, but not
ADAMTS5, could be induced with either IL-1 or TNF-α in an
NF-κB-dependent manner [49]. Although studies using trans-
genic mice [50-52] suggest that in these murine models of
degenerative joint disease, ADAMTS5 is the pathologically
induced aggrecanase, our data suggest that ADAMTS4 is the
aggrecanase induced by proinflammatory cytokines in the
human OA synovium. The identification of the primary aggre-
Figure 5
Effect of neutralisation of tumour necrosis factor (TNF)-α and/or inter- leukin (IL)-1 on the expression of matrix metalloproteinases (MMPs), tis- sue inhibitors of MMP (TIMPs), and link protein in osteoarthritis synovial  cell cultures Effect of neutralisation of tumour necrosis factor (TNF)-α and/or inter-
leukin (IL)-1 on the expression of matrix metalloproteinases (MMPs), tis-
sue inhibitors of MMP (TIMPs), and link protein in osteoarthritis synovial 
cell cultures. Two million cells per well were plated into 4 wells on a 24-
well plate and left untreated, incubated with the p75 TNF-soluble 
receptor-immunoglobulin fusion protein etanercept (Enbrel), incubated 
with a neutralising anti-IL-1β antibody, or incubated with a combination 
of etanercept and anti-IL-1β, as described in Materials and methods. 
After incubation for 48 hours, the cells were washed with phosphate-
buffered saline and the RNA extracted using Tri-reagent for reverse 
transcription-polymerase chain reaction analysis with oligonucleotide 
primers specific for MMP-1, MMP-3, MMP-13, TIMP-1, TIMP-2, TIMP-
3, and link protein. In all panels, analysis of GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) was used for comparison of gene 
expression.
Figure 6
Polymerase chain reaction data from matrix metalloproteinase (MMP),  link protein, and ADAMTS analysis, derived as described in Materials  and methods and in Figures 5 and 7 Polymerase chain reaction data from matrix metalloproteinase (MMP), 
link protein, and ADAMTS analysis, derived as described in Materials 
and methods and in Figures 5 and 7. Data are expressed as percent-
age of the gene expression in untreated cells, as standardised for 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase). The standard 
error of the mean is given (n = 4–5). ADAMTS, a disintegrin and metal-
loprotease with thrombospondin motifs; IL, interleukin.Arthritis Research & Therapy    Vol 8 No 6    Bondeson et al.
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canase (ADAMTS4 or ADAMTS5) involved in human OA still
needs to be conclusively established.
Conclusion
The results discussed above, as well as data from other
groups, would support the view that the macrophage is an
important player in promoting the production of inflammatory
and degradative mediators in the OA synovium. In particular,
our results indicate a role for both TNF-α and IL-1β in driving
inflammatory responses in OA. This would give priority to
attempts to modify macrophage function in OA, with the aim
of decreasing both inflammatory synovitis and the production
of degradative enzymes of importance for the progression of
the disease. Such studies would be of clear importance for
drug discovery and for the determination of novel therapeutic
targets in OA.
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